Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Food Effect Study of ABX-002 in Healthy Adults
NCT07652697Phase 1Completed
- Sponsor
- Autobahn Therapeutics
- Start
- Jan 2025
- Primary completion
- Feb 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of elunetirom (6 arms), sponsored by Autobahn Therapeutics. Primary endpoint: Bioequivalence between ABX-002 liquid and solid formulations at 8 weeks. Started Jan 2025; status: completed.
02
Drugs
elunetirom
Beyond the preview
Go deeper on NCT07652697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07652697.